PHIO - Phio Pharmaceuticals Corp. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PHIO

PHIO PHARMACEUTICALS CORP.

NASDAQ

$1.18

▼ DOWN 2.48% (-0.03)

KEY STATISTICS

Market Cap$13.71 M

52w High$4.19

52w Low$0.81

Dividend Yield—

Frequency—

P/E-0.91

Volume138.29K

Shares Out.11.62M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Robert J. Bitterman

COMPENSATION 2026

Salary$342,615

Stock Awards$43,245

Incentive Plan Pay$0

All Other Comp.$1,159

Total$387,019

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 10, 2012

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2024-07-05	Reverse	1:9
2023-01-26	Reverse	1:12
2020-01-15	Reverse	1:55
2018-01-08	Reverse	1:10
2016-04-18	Reverse	1:10
2013-07-30	Reverse	1:30
2013-07-24	Reverse	1:30

PRICE

$1.18 ▼ DOWN 2.48% (−$0.03)

OVERLAYS

About Phio Pharmaceuticals Corp.

https://www.phiopharma.com ↗

Phio Pharmaceuticals develops immuno-oncology therapeutics targeting tumor and immune cells using its INTASYL platform, including therapies like PH-762, PH-894, and PH-804, to enhance cancer immunotherapy, with collaborations in T cell-based treat...

INDUSTRY

Biotechnology

A PRODUCT PHIO PHARMACEUTICALS CORP. IS KNOWN FOR

PH-762

PH-762, Phio's lead clinical-stage INTASYL compound targeting PD-1 gene silencing, is in Phase 1b trials for skin cancers and is the company's most advanced immuno-oncology therapeutic.